Bringing a new therapy from first-in-human trials through regulatory approval often takes nearly a decade. During that journey, scientific uncertainty, changing evidence requirements, operational complexity and pauses between development activities can add years to an already demanding timeline.

Yet some therapies move substantially faster.

What allows these programs to progress differently? Are their timelines simply the result of an exceptional scientific breakthrough or favorable regulatory circumstances? Or do they reveal practical lessons that other clinical development teams can apply?

A new IQVIA white paper examines asset-level development cycle times for drugs first approved between 2020 and 2024. The analysis looks beyond individual success stories to identify the scientific, regulatory and operational conditions associated with faster drug development.

The findings reinforce an important principle: while uncertainty cannot be eliminated entirely, many sources of delay can be identified and addressed.

Why clinical development timelines remain difficult to predict

Drug development rarely follows a straight path. Programs evolve as new clinical evidence emerges, regulatory engagement helps clarify requirements and sponsors refine their understanding of an asset's potential in a changing competitive landscape.

For program leaders, the challenge is not simply to move faster. It is to make consequential decisions earlier without compromising scientific rigor, patient safety or evidence quality.

Several factors can make that difficult:

• Uncertainty about the most promising indication, patient population or development pathway.
• Protocol complexity that affects feasibility, site performance and patient recruitment.
• Evidence strategies that are not fully aligned with regulatory expectations.
• Sequential planning between phases that creates avoidable pauses.
• Fragmented data and organizational complexity or disorder that slow review and decision-making.
• Limited operational readiness to accelerate development when a program receives encouraging results.

When these risks are addressed only after they begin affecting execution, development teams lose valuable time. A more predictive approach focuses on recognizing where a program is likely to encounter friction and applying the right evidence, organization and planning earlier.

What can be learned from rapid approvals?

The white paper analyzes the period from the beginning of an asset's first Phase I trial through its first marketing approval. It compares development timelines across therapeutic areas and examines selected programs that progressed substantially faster than their peers.

The results demonstrate significant variation in development duration, both across and within therapeutic areas. They also show that rapid development cannot be attributed to one universal formula.

Several recurring factors were associated with shorter timelines, including:

• Development in rare diseases or areas of high unmet need.
• Strong and differentiated evidence emerging early.
• Use of expedited regulatory pathways when supported by the data.
• Novel modalities with the potential to address clearly defined patient needs.
• Focused development strategies and well-defined decision points.
• Operational models capable of acting quickly as new evidence became available.

These conditions do not guarantee acceleration. Organizations still need the planning, regulatory engagement and expertise to capitalize on these advantages. They do, however, show where development teams may have opportunities to anticipate risk, make decisions earlier and prevent manageable issues from becoming material delays

Faster development begins with better decisions

One of the clearest lessons from the analysis is that development speed is not solely an operational outcome. It is shaped by decisions made well before study execution begins.

Indication selection, endpoint strategy, regulatory planning, population and patient identification, operational planning and evidence generation are interconnected. A decision in one area can create constraints elsewhere in the program.

Predictive clinical development helps teams identify these dependencies earlier. By combining relevant data, analytics, scientific and regulatory expertise and operational insight, development teams can evaluate potential scenarios before committing to a path that may be difficult to execute nd have regulatory risks.

The objective is not certainty. It is a better understanding of the choices most likely to affect development speed, risk and value.

Reducing the white space between milestones

Highly visible activities such as study start-up, patient recruitment, database lock and regulatory submission receive considerable attention. Less visible gaps between these activities can be equally important.

Time can accumulate while teams wait for decisions, transfer information between functions, resolve inconsistencies or begin planning that could have started earlier. Individually, these delays may appear manageable. Across a multiyear clinical development program, they can become substantial.

The rapid-development examples explored in the white paper point to the value of:

• Early alignment across clinical, regulatory, operational and evidence teams.
• Scenario-based planning that anticipates likely decision points.
• Parallel preparation for upcoming development activities.
• Integrated data review that enables issues to be identified sooner.
• Clear governance and accountability for time-sensitive decisions.
• Technology and AI-enabled workflows supported by expert oversight.

These practices help development teams maintain momentum while continuing to respond appropriately to scientific and regulatory uncertainty.

Acceleration must remain evidence-led

The fastest programs should not become unrealistic benchmarks for every asset. Rare diseases, breakthrough evidence, novel modalities and expedited pathways can create circumstances that are not broadly reproducible.

The more useful question is not, "How can every program replicate the fastest approval?"

It is, "What can these programs teach us about identifying opportunities earlier and reducing delays that are within our control?"

That distinction matters. Sustainable acceleration does not come from compressing every activity or accepting unnecessary risk. It comes from making informed choices earlier, preparing for multiple scenarios and designing development programs for speed, quality and predictable execution.

Explore the evidence behind faster drug development

The IQVIA white paper examines development-duration patterns across therapeutic areas and explores selected rapid approvals in greater detail. It considers how scientific differentiation, rare disease focus, regulatory pathways, novel modalities, trial design and disciplined execution contributed to shorter timelines.

Download the white paper, Accelerating Drug Development: Insights from 2020–2024 Rapid Approvals, to learn how leading development programs anticipate risk, reduce avoidable delay and improve speed and predictability.